Comparative Pharmacology
Head-to-head clinical analysis: QUINACT versus QUINALAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QUINACT versus QUINALAN.
QUINACT vs QUINALAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Quinacrine is a 9-aminoacridine derivative that intercalates into DNA, inhibiting DNA replication and transcription, and also has antimalarial, anti-inflammatory, and antihelminthic properties. It inhibits phospholipase A2 and suppresses immune responses.
Quinidine (the active ingredient in Quinalan) is a class Ia antiarrhythmic agent that binds to and blocks voltage-gated sodium channels in cardiac myocytes, prolonging the action potential duration and effective refractory period. It also has vagolytic effects and blocks potassium channels.
100 mg orally three times daily.
10 mg orally once daily, may increase to 20 mg after 2 weeks if needed.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours (prolonged in renal impairment; CrCl <30 mL/min: 24-40 hours)
Terminal half-life: 12 hours (range 10-14) in normal renal function; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Renal: 60% unchanged; Biliary/fecal: 30% as metabolites; 10% other.
Category C
Category C
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)